Comparative Pharmacology
Head-to-head clinical analysis: E BASE versus ERYTHROMYCIN ETHYLSUCCINATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E BASE versus ERYTHROMYCIN ETHYLSUCCINATE.
E-BASE vs ERYTHROMYCIN ETHYLSUCCINATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
E-BASE is a proton pump inhibitor that irreversibly inhibits the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, suppressing gastric acid secretion.
Erythromycin ethylsuccinate is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It may also have anti-inflammatory and immunomodulatory effects.
25 mg orally once daily.
400-800 mg orally every 6 hours or 4 times daily; maximum 4 g/day. Intravenous form available but ethylester is oral only.
None Documented
None Documented
Terminal elimination half-life is approximately 6-8 hours in adults with normal renal function; may be prolonged in renal impairment.
Terminal elimination half-life: 1.5-2 hours in adults with normal renal function; extended to 5-6 hours in patients with severe hepatic impairment; not significantly altered by renal failure.
Renal excretion of unchanged drug accounts for approximately 60-70% of elimination; biliary/fecal excretion accounts for 20-30%.
Primarily hepatic metabolism and biliary excretion (80-90% as unchanged drug and metabolites into bile); renal excretion accounts for 5-15% of unchanged drug; fecal elimination of unabsorbed drug.
Category C
Category A/B
Macrolide Antibiotic
Macrolide Antibiotic